Analysis of Human ALS Tissues and Registry of ALS Patients
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Oct 1, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding Amyotrophic Lateral Sclerosis (ALS), a serious condition that leads to muscle weakness and is caused by the degeneration of nerve cells in the brain and spinal cord. The researchers aim to gain insights that could help identify markers of how the disease progresses and explore potential new treatments for ALS. Currently, there are no cures, and available treatments only help a little, so this study is important for finding better options for patients.
To participate in this trial, individuals must be over the age of 18 and have a confirmed diagnosis of ALS. Participants will need to provide written consent to join the study and agree to share some of their health information for research purposes. The trial is currently recruiting, and whether you are a patient or a family member, being part of this research could help advance our understanding of ALS and potentially lead to breakthroughs that benefit many people affected by this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over the age of 18
- • Established diagnosis of ALS
- • Able and willing to give written informed consent and must authorize release and use of protected health information
- Exclusion Criteria:
- • Patients below the age of 18
- • No diagnosis of ALS
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Jeffrey Loeb, MD
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials